Highest-materiality recent filing
Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance
Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
FDA agrees to remove ANA screening, reclassify lupus risk for Dianthus' claseprubart trials
FDA agreed to remove anti-nuclear antibodies (ANAs) as screening criteria for all ongoing and future claseprubart trials.
Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants
Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.
Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results
Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
Dianthus expects ~$514M cash at year-end 2025; CEO to present at JPM conference
Preliminary unaudited cash, cash equivalents, and short-term investments of ~$514M as of Dec 31, 2025.
Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26
Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.
Dianthus Therapeutics posts updated corporate presentation; no specific material changes disclosed
Updated corporate presentation posted on company's investor relations website on November 3, 2025.
Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones
Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).
Dianthus raises ~$270M in public offering of common stock and pre-funded warrants
Issued 6,487,879 common shares at $33.00/share and 1,112,121 pre-funded warrants at $32.999/share.
Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints
Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.
Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept
Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.
Dianthus director Moulder resigns; Read appointed as Class III director
Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.
On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.
On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.
Max materiality 0.85 · Median 0.68 · Most common event other_material